Literature DB >> 16944263

Salvage chemotherapy with a combination of irinotecan hydrochloride and mitomycin C in elderly Japanese patients with gynecological malignancies: a pilot study.

Hirohiko Tanaka1, Tomohisa Kihira, Yoshiyuki Nomura, Akinori Ishihara.   

Abstract

The efficacy and toxicity of salvage chemotherapy with a combination of irinotecan hydrochloride (CPT-11) and mitomycin C (MMC) in elderly Japanese patients with gynecological malignancies are reported. Six patients, aged 75 years or older, two with stage IV uterine cervical cancer and four with platinum- and taxane-resistant ovarian cancer, were treated. CPT-11 (120 mg/m(2)) was administered intravenously for 4 h with 500 ml of normal saline solution, followed by 3.5 mg/m(2) of MMC with 100 ml of normal saline, administered for 60 min, on days 1 and 15 and every 5 weeks thereafter. Six patients received a total of 24 courses of treatment, which provided an opportunity to explore, in a preliminary manner, the efficacy and toxicity of this approach. All patients demonstrated reasonable tolerance to this management strategy. There were no deaths attributable to toxicity. In a carefully selected patient population, CPT-11 and MMC chemotherapy could be administered to elderly Japanese patients with gynecological malignancies. Phase I and II studies are needed to confirm the feasibility of this treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16944263     DOI: 10.1007/s10156-006-0450-2

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  2 in total

1.  Preclinical antitumor activity of a nanoparticulate SN38.

Authors:  Mazin F Al-Kasspooles; Stephen K Williamson; David Henry; Jahna Howell; Fengui Niu; Charles J Decedue; Katherine F Roby
Journal:  Invest New Drugs       Date:  2013-01-09       Impact factor: 3.850

2.  Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers.

Authors:  Hiroyuki Moriya; Katsuhiko Saito; Nuala Helsby; Shigekazu Sugino; Michiaki Yamakage; Takeru Sawaguchi; Masahiko Takasaki; Hidenori Kato; Nahoko Kurosawa
Journal:  Oncol Lett       Date:  2014-04-08       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.